NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
89.52
-0.07 (-0.08%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close89.59
Open89.80
Bid89.17 x 900
Ask89.62 x 800
Day's Range89.39 - 90.12
52 Week Range64.78 - 90.21
Volume1,245,016
Avg. Volume2,728,495
Market Cap203.355B
Beta (3Y Monthly)0.54
PE Ratio (TTM)16.97
EPS (TTM)5.27
Earnings DateN/A
Forward Dividend & Yield2.83 (3.31%)
Ex-Dividend Date2019-03-04
1y Target Est99.50
Trade prices are not sourced from all markets
  • Financial Times2 days ago

    Bluebird Bio prices gene therapy at nearly $1.8m

    Bluebird Bio plans to price a new gene therapy for people with an inherited blood disorder at almost $1.8m per patient, and will try to persuade European healthcare systems to shell out for it by promising to only seek full payment if it works. Healthcare systems will pay an initial instalment of €315,000 but will only pay more instalments if the treatment helps the patient avoid blood transfusions. The Boston-based biotech start-up’s drug is part of a class of new transformative therapies that need to be administered only once and apply to a small patient population.

  • Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
    Zacks3 days ago

    Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

    Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

  • Top Analyst Reports for Visa, Netflix & Accenture
    Zacks3 days ago

    Top Analyst Reports for Visa, Netflix & Accenture

    Top Analyst Reports for Visa, Netflix & Accenture

  • Ligand Inks Oncology Drug Discovery Deal With PhoreMost
    Zacks3 days ago

    Ligand Inks Oncology Drug Discovery Deal With PhoreMost

    Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

  • Barrons.com3 days ago

    A Stock Fund Challenges the Definition of Growth. It’s Paying Off.

    Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.

  • Roche's Rituxan Gets Priority Review for Blood Disorder
    Zacks4 days ago

    Roche's Rituxan Gets Priority Review for Blood Disorder

    Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

  • Novartis Reports Data on Cosentyx for Psoriatic Arthritis
    Zacks4 days ago

    Novartis Reports Data on Cosentyx for Psoriatic Arthritis

    Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

  • Stoke Therapeutics boosts IPO goal by 40 percent
    American City Business Journals5 days ago

    Stoke Therapeutics boosts IPO goal by 40 percent

    Stoke now hopes to raise $123 million when it launches on the Nasdaq market in the coming weeks, according to documents newly filed with the SEC. It originally had filed plans for an $86.25 million initial public offering last month. Stoke could be the fifth Massachusetts biotech to go public this year.

  • Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug
    Zacks6 days ago

    Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

    Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

  • Moody's6 days ago

    Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable

    Moody's Investors Service has today assigned a B2 corporate family rating (CFR) and a B2-PD probability of default rating (PDR) to radiopharmaceutical products provider Curium Bidco S.a.r.l.. Concurrently, Moody's has assigned B2 ratings to the proposed senior secured first lien term loans B maturing in 2026, split into a €485 million equivalent US dollar-denominated tranche and a €250 million Euro-denominated tranche. Moody's has also assigned a B2 rating to the proposed pari passu ranking €120 million revolving credit facility (RCF) maturing in 2025. Senior secured first lien facilities shall be co-borrowed by Curium Bidco S.a.r.l., Curium Netherlands B.V. and Curium US Holdings LLC. The outlook is stable.

  • Roche Receives FTC Request for Further Data on Spark Buyout
    Zacks6 days ago

    Roche Receives FTC Request for Further Data on Spark Buyout

    Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

  • Celgene's Filing for Ozanimod Accepted for Review in US/EU
    Zacks9 days ago

    Celgene's Filing for Ozanimod Accepted for Review in US/EU

    The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

  • Benzinga9 days ago

    Sanofi's Leadership Transition: What You Need To Know

    With big pharma companies grappling with fundamental as well as geopolitical issues — including aging pipelines, key blockbuster drugs going off patent and a U.S. clampdown on drug pricing — many have turned to new leadership in recent years to reinvigorate growth. Sanofi has a mandatory 65-year-old retirement age for its CEO.

  • New Sanofi CEO 2019: 8 Things to Know About Paul Hudson
    InvestorPlace9 days ago

    New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

    There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring.Source: Shutterstock Here's what you need to know about Sanofi's (NASDAQ:SNY) new CEO. * The new Sanofi CEO is Paul Hudson. * He will be taking over the role of CEO from Brandicourt starting on Sept. 1, 2019. * Hudson's most recent work includes serving as the CEO of Novartis Pharmaceuticals (NYSE:NVS) and being a member on the Novartis Executive Committee. * The new Sanofi CEO also has plenty of experience working with pharmaceutical companies over the last 28 years. * Some of his major previous employers include Schering Plough, Astra Zeneca (NYSE:AZN) and Novartis. * This has given him plenty of experience working in the markets of the U.S., Japan and Europe. * It has also awarded him the experience needed to handle leadership through his previous management roles. * Paul Hudson will also be moving to Paris, France to serve in his role as CEO of the company, which has its headquarter there. * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% Serge Weinberg, Chairman of the Board of Directors for Sanofi, has this to say about the change.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are very pleased that Paul Hudson has agreed to join Sanofi. His skills and experience give him all the assets he needs to accelerate growth and lead the Group's adaptation to new strategic challenges, particularly in the areas of Research and Development and digital. His human values will enable him to mobilize all the energies and increase the agility, that a group such as Sanofi needs, to face the new challenges of our industry and the changes in healthcare systems around the world."SNY stock was up 5% as of Friday morning. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% * 7 Stocks to Buy That Don't Care About Tariffs * 5 Healthcare Stocks to Pick Up From the Wreckage As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post New Sanofi CEO 2019: 8 Things to Know About Paul Hudson appeared first on InvestorPlace.

  • Here’s What Hedge Funds Think About Novartis AG  (NVS)
    Insider Monkey9 days ago

    Here’s What Hedge Funds Think About Novartis AG (NVS)

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Sanofi Taps Novartis Executive as CEO in Race for New Drugs
    Bloomberg9 days ago

    Sanofi Taps Novartis Executive as CEO in Race for New Drugs

    Bringing in Paul Hudson as its next chief executive officer will help the French pharma giant bolster its pipeline of medicines and deal with growing U.S. pressure on drug prices. The 51-year-old British executive will take over in September from Olivier Brandicourt, 63, who’s retiring. Hudson has led Novartis’s pharma unit since 2016 and is credited with launching key medicines such as psoriasis treatment Cosentyx, which may become its top product this year with a projected $3.5 billion in sales.

  • Novartis Appoints New Pharma Unit Head, Gives Other Updates
    Zacks9 days ago

    Novartis Appoints New Pharma Unit Head, Gives Other Updates

    Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

  • Benzinga9 days ago

    The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 6) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: ...

  • Financial Times9 days ago

    Sanofi appoints top Novartis executive as new chief

    French drugmaker Sanofi has announced that a top executive from Swiss rival Novartis will succeed Olivier Brandicourt as CEO. Paul Hudson, who was most recently chief executive of the Novartis pharmaceuticals business and member of the executive committee of the overall group, will take over on September 1. since Sanofi’s diabetes treatments lost patent protection and came under pressure from cheaper rivals.

  • Investing.com9 days ago

    StockBeat: Markets Rise as Miserable German Data Boost QE Hopes

    By Geoffrey Smith

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zacks10 days ago

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

  • Incyte Begins Phase III Study for Treatment of Duct Cancer
    Zacks10 days ago

    Incyte Begins Phase III Study for Treatment of Duct Cancer

    Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

  • Was ASCO Quieter for Big Drug/Biotech Stocks This Year?
    Zacks10 days ago

    Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

    The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

  • Benzinga10 days ago

    The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...

  • Continued Smart M&A Moves Will Help Canopy Stock Break Out
    InvestorPlace11 days ago

    Continued Smart M&A Moves Will Help Canopy Stock Break Out

    Canopy Growth (NYSE:CGC) has been rangebound for awhile, but things are brewing in the industry that could help Canopy stock break out of its current range.Source: Shutterstock All the cannabis companies continue to make strides on the M&A front, positively impacting production volumes and overseas footprints. In particular, many of the news releases have been medical-related. After all, cannabis is viewed by many has having the largest market potential in the medical field.So, it was not a big surprise when Novartis AG (NYSE:NVS), a large global pharmaceutical company, was one of the first to invest in growing Canadian cannabis companies after they were able to list on major U.S. stock exchanges when they took controlling interest in Tilray Inc (NASDAQ:TLRY).InvestorPlace - Stock Market News, Stock Advice & Trading TipsOf course, the medical opportunity is massive, but Tilray competitor Canopy Growth has been aggressively pursuing a multi-pronged approach that inherently diversifies the future revenue streams. CGC's vision for THC as an ingredient in an array of consumer products separates them from an increasingly crowded industry. * 6 Big Dividend Stocks to Buy as Yields Plunge As a result of the company's innovative thinking, CGC is expanding the total addressable market when other companies are merely operating within the confines of conventional cannabinoid products. This is a strategy that should serve it well both in the short and long-term.Canopy stock has not been immune to the selloff in May, down almost 16 percent over the last month. However, it has faired far better than Tilray stock for example, which is down over 50 percent over the same period. It is a testament to better fundamentals and long-term prospects across multiple industries that CGC stock has weathered the correction much better than its peers. Cannabis as an IngredientIt bears repeating that cannabis as an ingredient in consumer products is pretty revelatory. Beyond vaping and pharmaceutical products, there has yet to be a major player truly re-imagining the future of cannabis. Enter Canopy Growth.They are a leader if not the leader in the Canadian medical market but also recognize the huge global market opportunity in consumer products. From sleep aids to beverages (alcoholic and athletic) and other health and wellness products, Canopy appears to believe that the sky really is the limit.Per the company, consumer products offer a $250 billion market opportunity. Just a few slices of that pie would do wonders for Canopy stock price.Right now, there are multiple human health clinical trials and animal health trials underway. Any positive news would be a catalyst for Canopy stock. And with the acquisition of Spectrum Therapeutics, it allows CGC to expand into the supplement business that complements the existing soft-gel business exceedingly well.The recent acquisition of This Works, takes CGC another step closer to realizing the latent potential in the wellness market. The Works Acquisition and Canopy Stock In late May, CGC acquired This Works for a CDN $74 million. They market themselves as a skincare and wellness company, but it is clear from their product lineup that they have a broader array of consumer products that CGC can benefit from.It is the sleep solution products and loyal customer base that have me excited about the prospects of the two company's integration. Right now, This Works is known for its deep sleep pillow spray, which they have sold 4.2 million of across Europe, the United Kingdom, China and the United States since launching in 2011.Not only does CGC improve its presence in the UK, but this collaboration also sets the stage for accelerated product development for a line of skincare and sleep solution products infused with CBD.It may be too early to say whether or not CBD has the potential to disrupt the cosmetic business, but the sleep solution industry is ripe for CGC to make its presence felt. As products start to gain traction in This Works' existing markets, this should be a big positive for CGC.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post Continued Smart M&A Moves Will Help Canopy Stock Break Out appeared first on InvestorPlace.